We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+7.52%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.33B
AUM Growth
+$713M
Cap. Flow
+$1.03B
Cap. Flow %
77.19%
Top 10 Hldgs %
46.07%
Holding
196
New
82
Increased
39
Reduced
17
Closed
45

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$20M
2
XLRN
Acceleron Pharma
XLRN
+$18.6M
3
TARA icon
Protara Therapeutics
TARA
+$12.9M
4
BTAI icon
BioXcel Therapeutics
BTAI
+$12M
5
VSTM icon
Verastem
VSTM
+$11M

Top Sells

Rank Stock Value
1
APTO
Aptose Biosciences, Inc.
APTO
+$5.72M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$4.63M
3
TGTX icon
TG Therapeutics
TGTX
+$3.51M
4
KALA icon
KALA BIO
KALA
+$3.39M
5
ARQL
Arqule Inc
ARQL
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 19.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
51
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$6.86M 0.52%
+35,000
New +$7.53M
SBBP
52
DELISTED
Strongbridge Biopharma plc.
SBBP
$6.41M 0.48%
+3,392,787
New +$8.82M
ACAD icon
53
CALL
Acadia Pharmaceuticals
ACAD
$4.43B
$6.34M 0.48%
+150,000
New +$6.18M
CCXI
54
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$6.03M 0.45%
+150,000
New +$6.37M
AVDL
55
CALL
DELISTED
Avadel Pharmaceuticals
AVDL
$5.96M 0.45%
+750,000
New +$5.76M
CYTK icon
56
CALL
Cytokinetics
CYTK
$10.5B
$5.89M 0.44%
+500,000
New +$6.38M
CVM icon
57
PUT
CEL-SCI Corp
CVM
$20.3M
$5.77M 0.43%
16,667
+6,660
+67% +$2.43M
KNSA icon
58
Kiniksa Pharmaceuticals
KNSA
$5.8B
$5.56M 0.42%
+358,924
New +$5.62M
KDMN
59
DELISTED
Kadmon Holdings, Inc.
KDMN
$5.52M 0.42%
+1,316,846
New +$5.67M
MYOK
60
CALL
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$5.32M 0.4%
+113,400
New +$7.27M
ZGNX
61
CALL
DELISTED
Zogenix, Inc.
ZGNX
$5.26M 0.4%
212,900
+208,300
+4,528% +$7.58M
SAGE
62
DELISTED
Sage Therapeutics
SAGE
$5.26M 0.4%
183,051
+50,051
+38% +$2.9M
XENE icon
63
Xenon Pharmaceuticals
XENE
$6.06B
$5.03M 0.38%
443,582
+200,112
+82% +$2.85M
CLVS
64
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$4.93M 0.37%
774,900
+261,200
+51% +$2.1M
INSM icon
65
CALL
Insmed
INSM
$21.4B
$4.81M 0.36%
300,000
+238,800
+390% +$5.66M
GBT
66
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.6M 0.35%
90,000
-10,000
-10% -$670K
CYTK icon
67
PUT
Cytokinetics
CYTK
$10.5B
$4.53M 0.34%
+384,400
New +$4.9M
RARE icon
68
CALL
Ultragenyx Pharmaceutical
RARE
$2.45B
$4.44M 0.33%
+100,000
New +$5.19M
SAGE
69
CALL
DELISTED
Sage Therapeutics
SAGE
$4.43M 0.33%
+154,300
New +$8.93M
KALA icon
70
KALA BIO
KALA
$14.1M
$4.34M 0.33%
198
-212
-52% -$3.39M
TCDA
71
DELISTED
Tricida, Inc. Common Stock
TCDA
$3.96M 0.3%
+179,800
New +$5.77M
BPMC
72
PUT
DELISTED
Blueprint Medicines
BPMC
$3.86M 0.29%
+66,000
New +$4.25M
ITCI
73
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.83M 0.29%
+249,002
New +$5.41M
ASND icon
74
PUT
Ascendis Pharma A/S
ASND
$16B
$3.76M 0.28%
+70,000
New +$9.1M
BMY.RT
75
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$3.61M 0.27%
+950,000
New +$3.13M
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2020 Portfolio in Review

As of Q1 2020, Ikarian Capital held 196 positions worth $1.33B, up 115% from $617M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Ikarian Capital deployed $1.03B of net new capital in Q1 2020, opening 82 new positions and adding to 39 existing holdings. Its largest new stake was Zogenix, Inc.: 549,459 shares worth $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 16% a quarter earlier.

On the sell side, the largest reduction was Aurinia Pharmaceuticals, an estimated $4.63M trimmed.

  • Ikarian Capital's largest Q1 2020 buy was Zogenix, Inc.: 549,459 shares worth $13.6M.
  • Ikarian Capital added most to Protara Therapeutics in Q1 2020, an estimated $12.9M increase.
  • Ikarian Capital's biggest Q1 2020 reduction was Aurinia Pharmaceuticals, cutting an estimated $4.63M.
  • Ikarian Capital fully exited Aptose Biosciences, Inc. in Q1 2020, selling an estimated $5.72M.
  • Ikarian Capital's ten largest holdings make up 46% of its $1.33B portfolio in Q1 2020.
  • Ikarian Capital opened 82 new positions and closed 45 in Q1 2020.
  • Ikarian Capital's portfolio value rose 115% quarter-over-quarter to $1.33B.

Based on Ikarian Capital's 13F filing for Q1 2020, filed 15 May 2020.